To test whether the HNSCC tumor environment is capable of potentiating Treg generation through IL-21 and PD-L1, we cocultured CD4+ T cells with tumor explants from HNSCC patients with or without IL-21 and/or an anti-PD-1 neutralizing antibody. The gene discussed is CD4; the disease is neoplasm.